Clinical Trial Update: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update for a Phase 1/2 study of BGB-16673 in combination with other agents for relapsed or refractory B-cell lymphomas, currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• B-cell Malignancies

Drugs mentioned

• BGB-16673

Snippet

Sponsor: BeOne Medicines | Conditions: B-cell Malignancy, Relapsed Cancer | Phase 1, Phase 2 | Status: RECRUITING